Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1057 studies found for:    Doxorubicin (liposomal) OR Doxil[TREATMENT] AND HIV [CONDITION]
Show Display Options
Rank Status Study
21 Completed Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Conditions: Sarcoma, Kaposi;   HIV Infections
Intervention: Drug: Doxorubicin hydrochloride (liposomal)
22 Terminated Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer
Condition: Ovarian Neoplasms
Interventions: Drug: Telcyta;   Drug: Liposomal Doxorubicin
23 Terminated
Has Results
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
Condition: Ovarian Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Topotecan
24 Terminated Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Condition: Ovarian Cancer
Interventions: Drug: CC-5013;   Drug: liposomal doxorubicin
25 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: epirubicin hydrochloride;   Drug: carboplatin;   Procedure: therapeutic conventional surgery;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
26 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Veliparib;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
27 Active, not recruiting Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
28 Completed Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Conditions: Sarcoma, Kaposi;   HIV Infections
Interventions: Drug: Doxorubicin hydrochloride (liposomal);   Drug: Bleomycin sulfate;   Drug: Vincristine sulfate
29 Completed
Has Results
Liposomal Doxorubicin Before Mastectomy in Treating Women With Invasive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Intraductal arm;   Drug: Intravenous arm
30 Completed Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
Condition: Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Drug: M200 (Volociximab);   Drug: Liposomal Doxorubicin
31 Completed Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma
Condition: Glioblastoma
Intervention: Drug: Pegylated Liposomal Doxorubicine
32 Recruiting A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Intervention: Device: Liposomal Doxorubicin Combined With ifosfamide
33 Recruiting Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus;   Drug: carboplatin;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
34 Completed Ixabepilone and Liposomal Doxorubicin in Treating Women With Advanced Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer
Conditions: Fallopian Tube Cancer;   Female Reproductive Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Breast Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage III Ovarian Epithelial Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions: Drug: ixabepilone;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: pharmacological study
35 Suspended Lenalidomide and Doxorubicin Hydrochloride Liposome in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: Lenalidomide;   Drug: pegylated liposomal doxorubicin hydrochloride
36 Completed Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection in Patients With Ovarian Cancer
Condition: Ovarian Carcinoma
Interventions: Drug: Liposomal Doxorubicin Hydrochloride;   Drug: Liposomal Doxorubicin Hydrochloride Injection
37 Completed
Has Results
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin;   Drug: Docetaxel
38 Terminated To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
Condition: Metastatic Breast Cancer
Interventions: Drug: Pegylated liposomal doxorubicin;   Drug: Capecitabine
39 Active, not recruiting Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: cyclophosphamide;   Drug: pegylated liposomal doxorubicin hydrochloride;   Drug: bortezomib;   Drug: dexamethasone
40 Recruiting Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Selinexor;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Dexamethasone

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years